Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884256 | 0.88 | LMNA (0.44) | KDM4EPDE4BALDH1A1TSHR | |
| SCHEMBL3881601 | 0.87 | TSHR (0.44) | KDM4EALDH1A1TSHR | |
| SCHEMBL3883577 | 0.85 | PDE4B (0.39) | KDM4EPDE4BALDH1A1TSHR | |
| SCHEMBL14452550 | 0.82 | NNMT (0.50) | KDM4EPDE4BKCNH2NNMTCSF1R | |
| SCHEMBL3880378 | 0.81 | KDM4E (0.47) | KDM4EPDE4BKCNH2NNMTCSF1R | |
| SCHEMBL13955928 | 0.77 | PDE4B (0.55) | KDM4EPDE4BKCNH2NNMTCSF1R | |
| SCHEMBL3880333 | 0.75 | ALDH1A1 (0.37) | KDM4EALDH1A1TSHR | |
| SCHEMBL3883281 | 0.73 | MEN1 (0.55) | KDM4EALDH1A1 | |
| SCHEMBL31661335 | 0.71 | PTGER4 (0.38) | NNMT | |
| SCHEMBL3881004 | 0.70 | ALDH1A1 (0.36) | KDM4EPDE4BALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1771443-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006002828-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CDK1, CDK17, CDK14 | KDM4E 1042/4885PDE4B 2464/4885KCNH2 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.